Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 637 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control gel Clear all
Recruiting Phase 4 Interventional Accepts healthy volunteers

Adaptions and Resiliency to Multi-Stressor OpeRations

NCT06455969
View directory record Official record
Conditions
Musculoskeletal Injury, Hypogonadism, Hormonal Contraception
Interventions
Goserelin 3.6 MG, Multi-Stressor Training, Testosterone gel (AndroGel 5g), Testosterone gel (AndroGel 1.25g)
Drug · Other
Lead sponsor
Bradley Nindl
Other
Eligibility
18 Years to 40 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 23, 2026, 1:44 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

NCT04214639
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-126 Gel, IDP-126 Vehicle Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
Bryant, Arkansas • Fremont, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 23, 2026, 1:44 AM EDT
Not listed Phase 2 Interventional

Efficacy and Safety Study of VB-1953 Topical Gel for Inflammatory Facial Acne Vulgaris

NCT03900676
View directory record Official record
Conditions
Acne Vulgaris
Interventions
VB-1953 - 2%, VB-1953 - 0% (Vehicle)
Drug
Lead sponsor
Vyome Therapeutics Inc.
Industry
Eligibility
9 Years to 45 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Ontario, California • Sherman Oaks, California • Brandon, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 23, 2026, 1:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)

NCT02450838
View directory record Official record
Conditions
Dengue
Interventions
V180, Alhydrogel™, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
3
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Oct 23, 2026, 1:44 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

ITT-5 Mechanisms of Spermatogenesis in Man

NCT02147964
View directory record Official record
Conditions
Gonadotropin Deficiency
Interventions
Testosterone 1% Gel, Acyline, Dutasteride, Ketoconazole, HCG, placebo dutasteride, placebo ketoconazole
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 23, 2026, 1:44 AM EDT
Terminated Phase 2 Interventional

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

NCT00117884
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
851B
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
22
States / cities
Colton, California • San Diego, California • Colorado Springs, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2016 · Synced Oct 23, 2026, 1:44 AM EDT
Completed Phase 2 Interventional Results available

Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea

NCT00989014
View directory record Official record
Conditions
Erythematotelangiectatic Rosacea
Interventions
CD07805/47, CD07805/47 placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
5
States / cities
Hot Springs, Arkansas • Fort Washington, Pennsylvania • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 23, 2026, 1:44 AM EDT
Completed Phase 2 Interventional

Prolongation of Contact Lens Comfortable Wear Duration by CLM2 Topical Gel

NCT03994406
View directory record Official record
Conditions
Contact Lens Discomfort, Contact Lens-induced Corneal Disorder, Contact Lens Acute Red Eye, Contact Lens-induced Corneal Fluorescein Staining
Interventions
CLM2 topical gel, Placebo topical gel
Drug
Lead sponsor
Glia, LLC
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 23, 2026, 1:44 AM EDT
Completed Phase 4 Interventional Results available

A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions

NCT02052752
View directory record Official record
Conditions
Skin Diseases
Interventions
3% Benzoyl Peroxide, 3% Benzoyl Peroxide Placebo, Neutrogena Rapid Clear®
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 45 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced Oct 23, 2026, 1:44 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer

NCT05930210
View directory record Official record
Conditions
Diabetic Foot Ulcer, Foot Ulcer, Diabetes Mellitus, Wound
Interventions
ENERGI-F703 GEL, ENERGI-F703 matched vehicle
Drug
Lead sponsor
Energenesis Biomedical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
Miami, Florida • Palmetto Bay, Florida • Columbus, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 23, 2026, 1:44 AM EDT
Completed Phase 3 Interventional

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

NCT01993225
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 12.5 mg/25 mg, Placebo Capsules, AndroGel 1.62%, Placebo Gel
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
9
States / cities
Birmingham, Alabama • Mobile, Alabama • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Oct 23, 2026, 1:44 AM EDT
Terminated Phase 4 Interventional Results available

Superficial Partial-Thickness Burn Study

NCT04601532
View directory record Official record
Conditions
Superficial Partial Thickness Burn
Interventions
Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser, Silver Sulfadiazine
Device · Drug
Lead sponsor
J. Peter Rubin, MD
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 23, 2026, 1:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Omega 7 + 3 Combination and Systemic Inflammation

NCT02155816
View directory record Official record
Conditions
Inflammation
Interventions
Omega 7 + 3, Omega 3, Placebo
Dietary Supplement
Lead sponsor
Appalachian State University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Oct 23, 2026, 1:44 AM EDT
Completed Phase 2 Interventional Results available

NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

NCT05005845
View directory record Official record
Conditions
Cutaneous Neurofibroma, Neurofibromatosis 1
Interventions
NFX-179 gel, Vehicle gel
Drug
Lead sponsor
NFlection Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
23
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Fremont, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 23, 2026, 1:44 AM EDT
Terminated Not applicable Interventional

Ultrasound for Diagnosis of Biliary Dyskinesia

NCT00737295
View directory record Official record
Conditions
Biliary Dyskinesia
Interventions
CCK Injection and Ultrasound
Procedure
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 89 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2010 · Synced Oct 23, 2026, 1:44 AM EDT
Terminated Phase 1Phase 2 Interventional

First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations

NCT04409145
View directory record Official record
Conditions
Venous Malformation, Lymphatic Malformation, Venolymphatic Malformation
Interventions
VT30
Drug
Lead sponsor
Venthera, Inc., a BridgeBio company
Industry
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 23, 2026, 1:44 AM EDT
Terminated Phase 3 Interventional

Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL

NCT06470451
View directory record Official record
Conditions
CTCL/ Mycosis Fungoides, CTCL, Mycosis Fungoides, Cutaneous T Cell Lymphoma
Interventions
Hypericin, Placebo
Drug
Lead sponsor
Soligenix
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
17
States / cities
Phoenix, Arizona • Scottsdale, Arizona • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 23, 2026, 1:44 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock Cellulite

NCT04677712
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy (EFP), Cellulite
Interventions
CCH-aaes, Compression, Cold Packs, Arnica Gel, INhance®, PDL
Drug · Other
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
8
States / cities
Scottsdale, Arizona • Sacramento, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 23, 2026, 1:44 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea

NCT00823901
View directory record Official record
Conditions
Rosacea
Interventions
Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel, Placebo gel
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Stanford, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Oct 23, 2026, 1:44 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris

NCT02616614
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Onexton, Clindamycin/benzoyl peroxide gel, Placebo
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
862 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
17
States / cities
Phoenix, Arizona • Chula Vista, California • La Mesa, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Oct 23, 2026, 1:44 AM EDT
Terminated Phase 3 Interventional

Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers

NCT01830348
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
DSC127, placebo vehicle gel
Drug
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
25
States / cities
Mobile, Alabama • Fair Oaks, California • Fresno, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 23, 2026, 1:44 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Collection of Gingival Crevicular Fluid From Periodontitis Patients

NCT00763048
View directory record Official record
Conditions
Gingival Diseases
Interventions
Fluoride, Fluoride, triclosan
Drug
Lead sponsor
Colgate Palmolive
Industry
Eligibility
26 Years to 68 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2011 · Synced Oct 23, 2026, 1:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel

NCT02650505
View directory record Official record
Conditions
Actinic Keratosis
Interventions
LEO 43204, LEO 43204 Vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
233 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 23, 2026, 1:44 AM EDT
Completed Not applicable Interventional

FiteBac Hand Sanitizer in the Management of Hand Dermatitis in Adults

NCT01950494
View directory record Official record
Conditions
Hand Dermatitis
Interventions
fiteBac Hand Sanitizer
Other
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Oct 23, 2026, 1:44 AM EDT